Protagenic Therapeutics Ownership 2024 | Who Owns Protagenic Therapeutics Now?

Overview RevenueFinancials Chart Transcripts

Institutional Ownership

14.16%

Insider Ownership

21.67%

Retail Ownership

64.17%

Institutional Holders

15.00

Protagenic Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	0.03%	-	32,951	32,951	100.00%	57,005,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.03%	-	25,399	25,399	100.00%	43,940,000	Mar 31, 2023
FNY INVESTMENT ADVISERS, LLC	0.02%	0.04%	18,750	18,750	100.00%	32,000	Mar 31, 2023
STATE STREET CORP	0.01%	-	13,812	13,812	100.00%	23,895,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.00%	-	2,764	2,764	100.00%	4,781,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.00%	0.00%	1,438	1,438	100.00%	2,000	Mar 31, 2023
UBS GROUP AG	0.00%	-	305	305	100.00%	528,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	23	23	100.00%	40,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	1	1	100.00%	2,000	Mar 31, 2023
MORGAN STANLEY	-	-	1	1	100.00%	2,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-1,552	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-25,899	-100.00%	-	Mar 31, 2023
WARBERG ASSET MANAGEMENT LLC	-	-	-	-5,000	-100.00%	-	Mar 31, 2023
VANGUARD GROUP INC	-	-	-	-59,078	-100.00%	-	Mar 31, 2023
CONCORDE ASSET MANAGEMENT, LLC	-	-	-	-4,180	-100.00%	-	Mar 31, 2023
FNY INVESTMENT ADVISERS, LLC	-	-	-	-18,750	-100.00%	-	Mar 31, 2023
CITADEL ADVISORS LLC	-	-	-	-5,871	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-4,289	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-3,495	-100.00%	-	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-2,764	-100.00%	-	Mar 31, 2023

Protagenic Therapeutics's largest institutional shareholder is VANGUARD GROUP INC, holding 0.03% of the company's total share outstanding, currently valued at $57.01M. The top 10 institutional shareholders own together 0.10% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
FNY INVESTMENT ADVISERS, LLC	0.02%	0.04%	18,750	18,750	100.00%	32,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.00%	0.00%	1,438	1,438	100.00%	2,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.00%	-	2,764	2,764	100.00%	4,781,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.03%	-	25,399	25,399	100.00%	43,940,000	Mar 31, 2023
VANGUARD GROUP INC	0.03%	-	32,951	32,951	100.00%	57,005,000	Mar 31, 2023
STATE STREET CORP	0.01%	-	13,812	13,812	100.00%	23,895,000	Mar 31, 2023
UBS GROUP AG	0.00%	-	305	305	100.00%	528,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	23	23	100.00%	40,000	Mar 31, 2023
MORGAN STANLEY	-	-	1	1	100.00%	2,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	1	1	100.00%	2,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-1,552	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-25,899	-100.00%	-	Mar 31, 2023
WARBERG ASSET MANAGEMENT LLC	-	-	-	-5,000	-100.00%	-	Mar 31, 2023
VANGUARD GROUP INC	-	-	-	-59,078	-100.00%	-	Mar 31, 2023
CONCORDE ASSET MANAGEMENT, LLC	-	-	-	-4,180	-100.00%	-	Mar 31, 2023
FNY INVESTMENT ADVISERS, LLC	-	-	-	-18,750	-100.00%	-	Mar 31, 2023
CITADEL ADVISORS LLC	-	-	-	-5,871	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-4,289	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-3,495	-100.00%	-	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-2,764	-100.00%	-	Mar 31, 2023

The largest Protagenic Therapeutics shareholder by % of total assets is FNY INVESTMENT ADVISERS, LLC. The company owns 18.75K shares of Protagenic Therapeutics (PTIX), representing 0.04% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	0.03%	-	32,951	32,951	100.00%	57,005,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.03%	-	25,399	25,399	100.00%	43,940,000	Mar 31, 2023
FNY INVESTMENT ADVISERS, LLC	0.02%	0.04%	18,750	18,750	100.00%	32,000	Mar 31, 2023
STATE STREET CORP	0.01%	-	13,812	13,812	100.00%	23,895,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.00%	-	2,764	2,764	100.00%	4,781,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.00%	0.00%	1,438	1,438	100.00%	2,000	Mar 31, 2023
UBS GROUP AG	0.00%	-	305	305	100.00%	528,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	23	23	100.00%	40,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	1	1	100.00%	2,000	Mar 31, 2023
MORGAN STANLEY	-	-	1	1	100.00%	2,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-1	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-23	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-1,552	-100.00%	-	Mar 31, 2023
VIRTU FINANCIAL LLC	-	-	-	-2,528	-100.00%	-	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-2,764	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-3,495	-100.00%	-	Mar 31, 2023
CONCORDE ASSET MANAGEMENT, LLC	-	-	-	-4,180	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-4,289	-100.00%	-	Mar 31, 2023
WARBERG ASSET MANAGEMENT LLC	-	-	-	-5,000	-100.00%	-	Mar 31, 2023
NORTHERN TRUST CORP	-	-	-	-5,622	-100.00%	-	Mar 31, 2023

As of Mar 31 2023, Protagenic Therapeutics's largest institutional buyer is VANGUARD GROUP INC. The company purchased 32.95K stocks of PTIX, valued at $57.01M.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	-	-	-	-59,078	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-25,899	-100.00%	-	Mar 31, 2023
FNY INVESTMENT ADVISERS, LLC	-	-	-	-18,750	-100.00%	-	Mar 31, 2023
STATE STREET CORP	-	-	-	-13,812	-100.00%	-	Mar 31, 2023
CITADEL ADVISORS LLC	-	-	-	-5,871	-100.00%	-	Mar 31, 2023
NORTHERN TRUST CORP	-	-	-	-5,622	-100.00%	-	Mar 31, 2023
WARBERG ASSET MANAGEMENT LLC	-	-	-	-5,000	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-4,289	-100.00%	-	Mar 31, 2023
CONCORDE ASSET MANAGEMENT, LLC	-	-	-	-4,180	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-3,495	-100.00%	-	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-2,764	-100.00%	-	Mar 31, 2023
VIRTU FINANCIAL LLC	-	-	-	-2,528	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-1,552	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-23	-100.00%	-	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-1	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	-	-	1	1	100.00%	2,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	1	1	100.00%	2,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	23	23	100.00%	40,000	Mar 31, 2023
UBS GROUP AG	0.00%	-	305	305	100.00%	528,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.00%	0.00%	1,438	1,438	100.00%	2,000	Mar 31, 2023

As of Mar 31 2023, Protagenic Therapeutics's biggest institutional seller is VANGUARD GROUP INC. The company sold -59.08K shares of PTIX, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	0.03%	-	32,951	32,951	100.00%	57,005,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.03%	-	25,399	25,399	100.00%	43,940,000	Mar 31, 2023
FNY INVESTMENT ADVISERS, LLC	0.02%	0.04%	18,750	18,750	100.00%	32,000	Mar 31, 2023
STATE STREET CORP	0.01%	-	13,812	13,812	100.00%	23,895,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.00%	-	2,764	2,764	100.00%	4,781,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.00%	0.00%	1,438	1,438	100.00%	2,000	Mar 31, 2023
UBS GROUP AG	0.00%	-	305	305	100.00%	528,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	23	23	100.00%	40,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	1	1	100.00%	2,000	Mar 31, 2023
MORGAN STANLEY	-	-	1	1	100.00%	2,000	Mar 31, 2023

Protagenic Therapeutics's largest new institutional shareholder by number of shares is VANGUARD GROUP INC, purchased 32.95K shares, valued at $57.01M, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	-	-	-	-59,078	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-25,899	-100.00%	-	Mar 31, 2023
FNY INVESTMENT ADVISERS, LLC	-	-	-	-18,750	-100.00%	-	Mar 31, 2023
STATE STREET CORP	-	-	-	-13,812	-100.00%	-	Mar 31, 2023
CITADEL ADVISORS LLC	-	-	-	-5,871	-100.00%	-	Mar 31, 2023
NORTHERN TRUST CORP	-	-	-	-5,622	-100.00%	-	Mar 31, 2023
WARBERG ASSET MANAGEMENT LLC	-	-	-	-5,000	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-4,289	-100.00%	-	Mar 31, 2023
CONCORDE ASSET MANAGEMENT, LLC	-	-	-	-4,180	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-3,495	-100.00%	-	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-2,764	-100.00%	-	Mar 31, 2023
VIRTU FINANCIAL LLC	-	-	-	-2,528	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-1,552	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-23	-100.00%	-	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-1	-100.00%	-	Mar 31, 2023

Protagenic Therapeutics's largest sold out institutional shareholder by shares sold is VANGUARD GROUP INC, sold -59.08K shares, valued at -, as of undefined.

Protagenic Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
VANGUARD INDEX FUNDS	0.00%	242,731	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	101,596	-	-	Feb 29, 2024
FIDELITY CONCORD STREET TRUST	0.00%	25,123	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	31,996	-31,996	-50.00%	Mar 31, 2024

Protagenic Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD INDEX FUNDS", owning 242.73K shares, compromising 0.00% of its total assets.

Protagenic Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Dec, 22	15	25.00%
30 Sep, 22	12	9.09%
30 Jun, 22	11	-8.33%
31 Mar, 22	12	-7.69%
31 Dec, 21	13	8.33%
30 Sep, 21	12	100.00%
30 Jun, 21	6	-

As of 31 Dec 22, 15 institutions are holding Protagenic Therapeutics's shares, representing an increase of 25.00% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Dec, 22	611,430	2.25%
30 Sep, 22	597,947	-1.11%
30 Jun, 22	604,644	-10.29%
31 Mar, 22	673,973	-29.32%
31 Dec, 21	953,552	-0.13%
30 Sep, 21	954,781	326.47%
30 Jun, 21	223,881	-

Protagenic Therapeutics (PTIX) has 611.43K shares outstanding as of 31 Dec 22, up 2.25% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Dec, 22	14.16%	7.40%
30 Sep, 22	13.84%	7.06%
30 Jun, 22	14.00%	5.72%
31 Mar, 22	15.64%	2.34%
31 Dec, 21	25.88%	4.84%
30 Sep, 21	23.12%	60.50%
30 Jun, 21	6.18%	-

As of 31 Dec 22, Protagenic Therapeutics is held by 14.16% institutional shareholders, representing a 7.40% growth compared to 30 Sep 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Dec, 22	6	20.00%
30 Sep, 22	5	25.00%
30 Jun, 22	4	-20.00%
31 Mar, 22	5	-28.57%
31 Dec, 21	7	-30.00%
30 Sep, 21	10	66.67%
30 Jun, 21	6	-

6 institutional shareholders have increased their position in PTIX stock as of 31 Dec 22 compared to 5 in the previous quarter (a 20.00% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Dec, 22	4	300.00%
30 Sep, 22	1	-50.00%
30 Jun, 22	2	-33.33%
31 Mar, 22	3	50.00%
31 Dec, 21	2	100.00%
30 Sep, 21	1	-
30 Jun, 21	-	-

4 institutional shareholders have reduced their position in PTIX stock as of 31 Dec 22 compared to 1 in the previous quarter (a 300.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Dec, 22	15	25.00%	611,430	2.25%	14.16%	7.40%	6	20.00%	4	300.00%
30 Sep, 22	12	9.09%	597,947	-1.11%	13.84%	7.06%	5	25.00%	1	-50.00%
30 Jun, 22	11	-8.33%	604,644	-10.29%	14.00%	5.72%	4	-20.00%	2	-33.33%
31 Mar, 22	12	-7.69%	673,973	-29.32%	15.64%	2.34%	5	-28.57%	3	50.00%
31 Dec, 21	13	8.33%	953,552	-0.13%	25.88%	4.84%	7	-30.00%	2	100.00%
30 Sep, 21	12	100.00%	954,781	326.47%	23.12%	60.50%	10	66.67%	1	-
30 Jun, 21	6	-	223,881	-	6.18%	-	6	-	-	-

Protagenic Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Oct 13, 2023	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	8,000	$0.81	$6.48K	45,815
May 18, 2022	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	8,000	$0.72	$5.76K	151,260
May 18, 2022	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	23,000	$0.71	$16.33K	143,260
Jun 03, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	16,900	$4.98	$84.16K	50,000
Jun 03, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	100	$4.98	$498.00	33,100
Jun 01, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	3,000	$4.98	$14.94K	33,000
May 20, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	18,000	$4.98	$89.64K	30,000
May 20, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	12,000	$4.98	$59.76K	12,000

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Oct 13, 2023	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	8,000	$0.81	$6.48K	45,815
May 18, 2022	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	8,000	$0.72	$5.76K	151,260
May 18, 2022	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	23,000	$0.71	$16.33K	143,260
Jun 03, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	16,900	$4.98	$84.16K	50,000
Jun 03, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	100	$4.98	$498.00	33,100
Jun 01, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	3,000	$4.98	$14.94K	33,000
May 20, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	18,000	$4.98	$89.64K	30,000
May 20, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	12,000	$4.98	$59.76K	12,000

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
May 05, 2021	Barrage Khalil	director	-	M-Exempt	Sell	45,000	$1.25	$56.25K	315,000

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Apr 01, 2024	WRIGHT TIMOTHY R	director	-	A-Award	Buy	21,250	$1.74	$36.98K	21,250
Mar 29, 2024	Stein Robert Benjamin	director	-	A-Award	Buy	75,000	$1.74	$130.50K	75,000
Mar 29, 2024	Barrage Khalil	director	-	A-Award	Buy	22,500	$1.74	$39.15K	22,500
Mar 29, 2024	Buell Jennifer	director	-	A-Award	Buy	75,000	$1.74	$130.50K	75,000
Mar 29, 2024	ARMEN GARO H	director, 10 percent owner, officer	Executive Chairman	A-Award	Buy	250,000	$1.74	$435.00K	250,000
Mar 29, 2024	Corvese Brian	director	-	A-Award	Buy	43,750	$1.74	$76.13K	43,750
Mar 29, 2024	Arrow Alexander K.	officer	Chief Financial Officer	A-Award	Buy	100,000	$1.74	$174.00K	100,000
Oct 13, 2023	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	8,000	$0.81	$6.48K	45,815
May 18, 2022	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	8,000	$0.72	$5.76K	151,260
May 18, 2022	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	23,000	$0.71	$16.33K	143,260
Jun 03, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	16,900	$4.98	$84.16K	50,000
Jun 03, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	100	$4.98	$498.00	33,100
Jun 01, 2021	Barrage Khalil	director	-	A-Award	Buy	180,000	$3.65	$657.00K	180,000
Jun 01, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	3,000	$4.98	$14.94K	33,000
May 20, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	18,000	$4.98	$89.64K	30,000
May 20, 2021	Arrow Alexander K.	officer	Chief Financial Officer	P-Purchase	Buy	12,000	$4.98	$59.76K	12,000
May 05, 2021	Barrage Khalil	director	-	M-Exempt	Buy	120,000	$1.75	$210.00K	410,000
May 05, 2021	Barrage Khalil	director	-	M-Exempt	Sell	45,000	$1.25	$56.25K	315,000
May 05, 2021	Barrage Khalil	director	-	M-Exempt	Buy	45,000	$1.75	$78.75K	290,000
May 05, 2021	Barrage Khalil	director	-	M-Exempt	Buy	150,000	$1.25	$187.50K	245,000

The last insider sell of Protagenic Therapeutics's stock was made by Barrage Khalil on May 05 2021, selling 45,000 shares at $1.25 per share (valued at $56.25K). The last insider buy of PTIX was made by Arrow Alexander K. on Oct 13 2023, buying 8,000 shares at $0.81 per share (worth $6.48K).

Protagenic Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q4 2023	1	-	-
Q2 2022	1	-	-
Q4 2006	-	1	-

1 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Protagenic Therapeutics's insiders, as of Q4 2023.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q4 2023	1	-	-
Q2 2022	1	-	-
Q4 2006	-	1	-

As of Q4 2023, Insider owners conducted 1 open market buy trades and 0 open market sell trades of Protagenic Therapeutics's stocks.

Protagenic Therapeutics Peer Ownership

Ticker	Company
CYT	Cyteir Therapeutics, Inc.
AVTE	Aerovate Therapeutics, Inc.
ACRV	Acrivon Therapeutics, Inc. Common Stock
ANTX	AN2 Therapeutics, Inc.
ELDN	Eledon Pharmaceuticals, Inc.
RZLT	Rezolute, Inc.
TPST	Tempest Therapeutics, Inc.
ADAG	Adagene Inc.

PTIX Ownership FAQ

Who Owns Protagenic Therapeutics?

Protagenic Therapeutics is owned by institutional shareholders (14.16%), insiders (21.67%), and public (64.17%). The largest institutional shareholder of Protagenic Therapeutics is VANGUARD GROUP INC (0.03% of total shares) and the top mutual fund owner is VANGUARD INDEX FUNDS (0.00% of total shares).

Who are the major institutional shareholders of Protagenic Therapeutics?

Protagenic Therapeutics's major institutional shareholders are VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, FNY INVESTMENT ADVISERS, LLC, STATE STREET CORP, and ADVISOR GROUP HOLDINGS, INC.. The top five shareholders own together 0.09% of the company's share outstanding.

How many Protagenic Therapeutics shareholders are there?

As of Dec 2022, there are 15 institutional shareholders of Protagenic Therapeutics.

What percentage of Protagenic Therapeutics is owned by VANGUARD GROUP INC?

VANGUARD GROUP INC owns 32.95K shares of Protagenic Therapeutics, representing 0.03% of the company's total shares outstanding, valued at $57M (as of Mar 2023).

What percentage of Protagenic Therapeutics is owned by GEODE CAPITAL MANAGEMENT, LLC?

As of Mar 2023, GEODE CAPITAL MANAGEMENT, LLC holds 25.4K shares of Protagenic Therapeutics (PTIX), compromising 0.03% of the company, valued at $43.94M.

What percentage of Protagenic Therapeutics is owned by FNY INVESTMENT ADVISERS, LLC?

FNY INVESTMENT ADVISERS, LLC is the third largest holder of Protagenic Therapeutics. The company owns 18.75K of the company's shares outstanding (worth $32K).